1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 1,267 results.

$Thumbnail for Treatment Discontinuation and Dose Modifications Associated With Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis$

MM - 079

Treatment Discontinuation and Dose Modifications Associated With Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis

Rithika Manjunatha Reddy

Poster Presenter: Rithika Manjunatha Reddy

MM - 082

Prognostic Impact of Interphase FISH in Multiple Myeloma: Single-Center Irish Experience

Tushar Pramod

Poster Presenter: Tushar Pramod

SOHO 2026 Annual Meeting

Topics

Treatment Discontinuation and Dose Modifications Associated With Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis

Prognostic Impact of Interphase FISH in Multiple Myeloma: Single-Center Irish Experience

Is IgA Isotype an Independent Adverse Prognostic Factor in Multiple Myeloma? A Systematic Review and Meta-Analysis of Cytogenetic Risk, Survival, and Treatment Outcomes in the Modern Era

Real-World Outcomes of Primary and Secondary Plasma Cell Leukemia in the Era of CAR-T and Bispecific Antibody Therapy: A Single-Center Experience

Efficacy and Safety of Chimeric Antigen Receptor T-cell (CAR-T) Therapy Against Standard Regimen in Relapsed/Refractory Multiple Myeloma: A Meta-Analysis

Clinical Investigators' Selection of Induction and Maintenance Therapy for Patients With Newly Diagnosed Multiple Myeloma Eligible and Ineligible for Transplant

Target-Specific Toxicity Phenotypes of BCMA- vs GPRC5D-Directed Bispecific Antibodies in Multiple Myeloma: A FAERS Analysis

OPTec/OPTal: A Phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

GLP-1 Receptor Agonists and Venous Thromboembolism Risk in Multiple Myeloma